FDA has decided to join the real world next year – or at least, explore it, in terms of what type of data it will consider from innovator drug makers.
FDA To Join The 'Real World' Under PDUFA VI
Regulators pledge to explore the use of real-world evidence, strengthen the patient's voice in drug review, and boost the agency's postmarketing surveillance abilities as part of sixth round of user fee program with industry.
